Healthcare provider profile · identity verified

Ali R Jaffery, MD

Internal Medicine · DULUTH, MN · NPI 1235690199

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	201	62
Losartan Potassium	Losartan Potassium	199	58
Amlodipine Besylate	Amlodipine Besylate	173	53
Omeprazole	Omeprazole	165	51
Levothyroxine Sodium	Levothyroxine Sodium	159	43
Gabapentin	Gabapentin	136	31
Metoprolol Succinate	Metoprolol Succinate	129	41
Rosuvastatin Calcium	Rosuvastatin Calcium	122	36
Pantoprazole Sodium	Pantoprazole Sodium	113	27
Lisinopril	Lisinopril	106	33
Tamsulosin Hcl	Tamsulosin Hcl	100	34
Hydrochlorothiazide	Hydrochlorothiazide	97	30
Pravastatin Sodium	Pravastatin Sodium	93	20
Jantoven	Warfarin Sodium	90	suppressed
Metformin Hcl	Metformin Hcl	88	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	84	19
Trazodone Hcl	Trazodone Hcl	82	25
Metformin Hcl Er	Metformin Hcl	74	23
Simvastatin	Simvastatin	70	19
Ozempic	Semaglutide	65	suppressed
Furosemide	Furosemide	63	23
Pregabalin	Pregabalin	55	14
Finasteride	Finasteride	53	12
Metoprolol Tartrate	Metoprolol Tartrate	51	suppressed
Sertraline Hcl	Sertraline Hcl	50	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	13
Jardiance	Empagliflozin	48	suppressed
Montelukast Sodium	Montelukast Sodium	45	13
Xarelto	Rivaroxaban	42	suppressed
Eliquis	Apixaban	40	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Tramadol Hcl	Tramadol Hcl	39	suppressed
Clonazepam	Clonazepam	37	suppressed
Allopurinol	Allopurinol	34	11
Warfarin Sodium	Warfarin Sodium	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	14
Memantine Hcl	Memantine Hcl	32	suppressed
Potassium Chloride	Potassium Chloride	32	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	13
Valsartan	Valsartan	31	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Baclofen	Baclofen	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	12
Mounjaro	Tirzepatide	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Famotidine	Famotidine	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	26	suppressed
Meloxicam	Meloxicam	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Carvedilol	Carvedilol	24	suppressed
Estradiol	Estradiol	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	23	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Celecoxib	Celecoxib	22	11
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Alprazolam	Alprazolam	21	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Prednisone	Prednisone	21	16
Risperidone	Risperidone	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Primidone	Primidone	20	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Torsemide	Torsemide	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	18	18
Hydrocortisone	Hydrocortisone	18	suppressed
Sulfasalazine	Sulfasalazine	18	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Topiramate	Topiramate	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Morphine Sulfate	Morphine Sulfate	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	11
Atenolol	Atenolol	13	suppressed
Digoxin	Digoxin	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	12	suppressed
Prazosin Hcl	Prazosin Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error